BioCryst Pharmaceuticals, Inc. — Company profile
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 8.47 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.16B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Details
| Name | BioCryst Pharmaceuticals, Inc. |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Employees | 435 |
| Founded | 1986 |
| Ipo Date | 1994-03-03 |
| Ceo | Charles Gayer |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US09058V1035 |
| Cusip | 09058V103 |
| Cik | 0000882796 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Charles K. Gayer | Chief Executive Officer, President and Director |
| Babar Ghias | Chief Financial Officer and Head of Corporate Development |
| Alane P. Barnes | Senior Vice President, Chief Legal Officer and Corporate Secretary |
| John Ruesch | Chief Technical Operations Officer |
| Dr. David W. Jenkins M.A., Ph.D. | Chief Scientific Officer |
| Nick Wilder | Manager of Investor Relations |
| Stephanie Angelini | Chief People Officer and Communications Officer |
| Dr. William P. Sheridan MBBS | Chief Development Officer |
| Dr. Yarlagadda S. Babu Ph.D. | Chief Discovery Officer |
| Jinky Ang Rosselli | Chief Data Innovation Officer |
Contact
| Address | 4505 Emperor Boulevard, Suite 200, Durham, North Carolina 27703, United States |
| Phone | 919 859 1302 |
| Website | https://www.biocryst.com |